{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:46:03Z","timestamp":1789706763051,"version":"4.0.1"},"reference-count":120,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.lpm.2013.01.053","type":"journal-article","created":{"date-parts":[[2013,4,9]],"date-time":"2013-04-09T05:01:59Z","timestamp":1365483719000},"page":"930-950","source":"Crossref","is-referenced-by-count":31,"special_numbering":"P1","title":["Diagnostic et traitement des hypercholest\u00e9rol\u00e9mies familiales (HF) chez l\u2019adulte\u00a0: recommandations de la Nouvelle soci\u00e9t\u00e9 fran\u00e7aise d\u2019ath\u00e9roscl\u00e9rose (NSFA)"],"prefix":"10.1016","volume":"42","author":[{"given":"Michel","family":"Farnier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Bruckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Boileau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Krempf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2013.01.053_bib0005","unstructured":"Afssaps. Prise en charge th\u00e9rapeutique du patient dyslipid\u00e9mique. Recommandations mars 2005. www.agmed.sante.gouv.fr."},{"key":"10.1016\/j.lpm.2013.01.053_bib0010","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Educations Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2013.01.053_bib0015","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias","volume":"32","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2013.01.053_bib0020","first-page":"465","article-title":"Recommandations pour la prise en charge des hypercholest\u00e9rol\u00e9mies chez l\u2019enfant","volume":"22","author":"Luc","year":"2010","journal-title":"STV"},{"key":"10.1016\/j.lpm.2013.01.053_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-0004.2007.00915.x","article-title":"Genetic heterogeneity of autosomal dominant hypercholesterolemia","volume":"73","author":"Varret","year":"2008","journal-title":"Clin Genet"},{"key":"10.1016\/j.lpm.2013.01.053_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(02)00330-1","article-title":"A review on the diagnosis, natural history, and treatment of familial hypercholesterolemia","volume":"168","author":"Marks","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.lpm.2013.01.053_bib0035","doi-asserted-by":"crossref","first-page":"a1095","DOI":"10.1136\/bmj.a1095","article-title":"Familial hypercholesterolemia: summary of NICE guidance","volume":"337","author":"Wierzbicki","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.lpm.2013.01.053_bib0040","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.atherosclerosis.2007.12.024","article-title":"Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors","volume":"200","author":"Alonso","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.lpm.2013.01.053_bib0045","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1161\/01.CIR.92.3.290","article-title":"Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation","volume":"92","author":"Ferrieres","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2013.01.053_bib0050","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-2796.2004.01405.x","article-title":"The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400\u00a0patients","volume":"256","author":"Jansen","year":"2004","journal-title":"J Intern Med"},{"key":"10.1016\/j.lpm.2013.01.053_bib0055","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1136\/hrt.2003.022764","article-title":"Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia","volume":"90","author":"Neil","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.lpm.2013.01.053_bib0060","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1136\/jmg.2006.038356","article-title":"Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk","volume":"43","author":"Humphries","year":"2006","journal-title":"J Med Gen"},{"key":"10.1016\/j.lpm.2013.01.053_bib0065","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/aje\/kwh237","article-title":"Familial hypercholesterolemia and coronary heart disease: a HuGE association review","volume":"160","author":"Austin","year":"2004","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.lpm.2013.01.053_bib0070","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.amjcard.2006.06.039","article-title":"Identifying patients for aggressive cholesterol lowering: the risk curve concept","volume":"98","author":"Robinson","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.lpm.2013.01.053_bib0075","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1161\/CIRCULATIONAHA.108.835470","article-title":"Systematic examination of the updated Framingham heart study general cardiovascular risk profile","volume":"120","author":"Marma","year":"2009","journal-title":"Circulation"},{"issue":"Suppl","key":"10.1016\/j.lpm.2013.01.053_bib0080","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.jacl.2011.03.451","article-title":"Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Robinson","year":"2011","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.lpm.2013.01.053_bib0085","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein (a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2013.01.053_bib0090","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.atherosclerosis.2011.02.007","article-title":"Lipoprotein (a) levels in coronary heart disease-susceptible and-resistant patients with familial hypercholesterolemia","volume":"216","author":"Nenseter","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.lpm.2013.01.053_bib0095","doi-asserted-by":"crossref","first-page":"E1811","DOI":"10.1002\/humu.21348","article-title":"Molecular spectrum of autosomal dominant hypercholesterolemia in France","volume":"31","author":"Marduel","year":"2010","journal-title":"Hum Mutat"},{"key":"10.1016\/j.lpm.2013.01.053_bib0100","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1146\/annurev.ge.24.120190.001025","article-title":"The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein","volume":"24","author":"Hobbs","year":"1990","journal-title":"Annu Rev Genet"},{"key":"10.1016\/j.lpm.2013.01.053_bib0105","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/humu.1380010602","article-title":"Molecular genetics of the LDL receptor gene in familial hypercholesterolemia","volume":"1","author":"Hobbs","year":"1992","journal-title":"Hum Mutat"},{"key":"10.1016\/j.lpm.2013.01.053_bib0110","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9\u00a0cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.lpm.2013.01.053_bib0115","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/ard.2005.040766","article-title":"Familial hypercholesterolaemia commonly presents with Achilles tenosynovitis","volume":"65","author":"Beeharry","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.lpm.2013.01.053_bib0120","doi-asserted-by":"crossref","first-page":"d5497","DOI":"10.1136\/bmj.d5497","article-title":"Xanthelasmata, arcus corneae, and ischaemic vascular disease and death in general population: prospective cohort study","volume":"343","author":"Christoffersen","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.lpm.2013.01.053_bib0125","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1515\/CCLM.2008.135","article-title":"Development of sensitive and specific age- and gender-specific low density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing","volume":"46","author":"Starr","year":"2008","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.lpm.2013.01.053_bib0130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1055\/s-2004-822984","article-title":"Clinical, diagnostic, and therapeutic aspects of familial hypercholesterolemia","volume":"4","author":"van Aalst-Cohen","year":"2004","journal-title":"Semin Vasc Med"},{"key":"10.1016\/j.lpm.2013.01.053_bib0135","unstructured":"Identification and management of familial hypercholesterolemia. NICE 2008. www.nice.org.uk."},{"key":"10.1016\/j.lpm.2013.01.053_bib0140","unstructured":"Nouvelle Soci\u00e9t\u00e9 fran\u00e7aise d\u2019ath\u00e9roscl\u00e9rose. www.nsfa.asso.fr."},{"key":"10.1016\/j.lpm.2013.01.053_bib0145","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1399-0004.2009.01356.x","article-title":"Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project","volume":"77","author":"Taylor","year":"2010","journal-title":"Clin Genet"},{"key":"10.1016\/j.lpm.2013.01.053_bib0150","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/1474651409339989","article-title":"Cascade screening for familial hypercholesterolaemia and its effectiveness in the prevention of vascular disease","volume":"9","author":"Herman","year":"2009","journal-title":"Br J Diabet Vasc Dis"},{"key":"10.1016\/j.lpm.2013.01.053_bib0155","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/ncpcardio0941","article-title":"Familial hypercholesterolemia: a missed opportunity in preventive medicine","volume":"4","author":"Watts","year":"2007","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.lpm.2013.01.053_bib0160","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1055\/s-2004-822987","article-title":"Advanced method for the identification of patients with inherited hypercholesterolemia","volume":"4","author":"Defesche","year":"2004","journal-title":"Semin Vasc Med"},{"key":"10.1016\/j.lpm.2013.01.053_bib0165","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1053\/euhj.2002.3281","article-title":"Cost-effectiveness of a family and DNA based screening programme on familial hypercholesterolemia in The Netherlands","volume":"23","author":"Marang-van de Mheen","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2013.01.053_bib0170","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-2004-822992","article-title":"Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in the Netherlands","volume":"4","author":"Wonderling","year":"2004","journal-title":"Semin Vasc Med"},{"key":"10.1016\/j.lpm.2013.01.053_bib0175","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(00)03587-X","article-title":"Review of first 5\u00a0years of screening for familial hypercholesterolemia in the Netherlands","volume":"357","author":"Umans-Eckenhausen","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2013.01.053_bib0180","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2217\/clp.10.39","article-title":"Developing and applying clinically useful approaches to identify individuals with familial hypercholesterolemia in the UK","volume":"5","author":"Humphries","year":"2010","journal-title":"Clin Lipidol"},{"key":"10.1016\/j.lpm.2013.01.053_bib0185","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/hrt.2006.107391","article-title":"Identifying patients with familial hypercholesterolemia in primary care: an informatics-based approach in one primary care centre","volume":"94","author":"Gray","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.lpm.2013.01.053_bib0190","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/hrt.2008.162909","article-title":"Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia","volume":"95","author":"Minhas","year":"2009","journal-title":"Heart"},{"key":"10.1016\/j.lpm.2013.01.053_bib0195","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0021-9150(00)00733-4","article-title":"Sustained long-term improvement of arterial endothelial function in heterozygous familial hypercholesterolemia patients treated with simvastatin","volume":"157","author":"Alonso","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.lpm.2013.01.053_bib0200","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1001\/jama.1990.03450230043027","article-title":"Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regiments","volume":"264","author":"Kane","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.lpm.2013.01.053_bib0205","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1161\/01.CIR.93.10.1826","article-title":"LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis","volume":"93","author":"Kroon","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2013.01.053_bib0210","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(00)04053-8","article-title":"Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial","volume":"357","author":"Smilde","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2013.01.053_bib0215","doi-asserted-by":"crossref","first-page":"a2423","DOI":"10.1136\/bmj.a2423","article-title":"Efficacy of statins in familial hypercholesterolaemia: a long-term cohort study","volume":"337","author":"Versmissen","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.lpm.2013.01.053_bib0220","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1093\/eurheartj\/ehn422","article-title":"Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study","volume":"29","author":"Neil","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2013.01.053_bib0225","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444\u00a0patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"Scandinavian Simvastatin Survival Study G","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2013.01.053_bib0230","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2013.01.053_bib0235","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056\u00a0participants in 14\u00a0randomised trials of statins","volume":"366","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2013.01.053_bib0240","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000\u00a0participants in 26\u00a0randomised trials","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2013.01.053_bib0245","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.jacc.2005.05.085","article-title":"Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis","volume":"46","author":"Robinson","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2013.01.053_bib0250","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0021-9681(78)90076-0","article-title":"Colestipol hydrochloride in hypercholesterolemic patients\u2013effect on serum cholesterol and mortality","volume":"31","author":"Dorr","year":"1978","journal-title":"J Chron Dis"},{"key":"10.1016\/j.lpm.2013.01.053_bib0255","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.lpm.2013.01.053_bib0260","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","year":"1975","journal-title":"JAMA"},{"key":"10.1016\/j.lpm.2013.01.053_bib0265","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jacc.2008.10.024","article-title":"Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk","volume":"53","author":"Robinson","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2013.01.053_bib0270","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1056\/NEJM199010043231404","article-title":"Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control on the Hyperlipidemias (POSCH)","volume":"323","author":"Buchwald","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2013.01.053_bib0275","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amjcard.2004.09.015","article-title":"Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia","volume":"95","author":"van Wissen","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.lpm.2013.01.053_bib0280","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia","volume":"358","author":"Kastelein","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2013.01.053_bib0285","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1586\/14779072.6.6.781","article-title":"Is it over for ezetimibe?","volume":"6","author":"Robinson","year":"2008","journal-title":"Exp Rev Cardiovasc Ther"},{"key":"10.1016\/j.lpm.2013.01.053_bib0290","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.atherosclerosis.2010.06.040","article-title":"Long-term LDL-C lowering in heterozygous familial hypercholesterolemia normalizes carotid intima-media thickness","volume":"212","author":"Sivalaratnam","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.lpm.2013.01.053_bib0300","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/eurheartj\/ehl482","article-title":"Carotid intima-media thickness and coronary atherosclerosis: weak or strong relations?","volume":"28","author":"Bots","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2013.01.053_bib0305","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1161\/ATVBAHA.107.160408","article-title":"Vascular calcifications in homozygote familial hypercholesterolemia","volume":"28","author":"Awan","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.lpm.2013.01.053_bib0310","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.amjcard.2008.07.035","article-title":"Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia","volume":"102","author":"Kolansky","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.lpm.2013.01.053_bib0315","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/hrt.2010.220699","article-title":"CT coronary plaque burden in asymptomatic patients with familial hypercholesterolaemia","volume":"97","author":"Neefjes","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.lpm.2013.01.053_bib0320","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.atherosclerosis.2010.10.001","article-title":"Evaluation of subclinical atherosclerosis by computed tomography coronary angiography and its association with risk factors in familial hypercholesterolemia","volume":"213","author":"Miname","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.lpm.2013.01.053_bib0325","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ahj.2008.08.021","article-title":"Aortic calcifications in familial hypercholesterolemia: potential role of the low-density lipoprotein receptor gene","volume":"157","author":"Alrasadi","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.lpm.2013.01.053_bib0330","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0022-2275(20)30168-1","article-title":"Efficacy of therapeutic lifestyle change\/step2\u00a0diet in moderately hypercholesterolemic middle-aged and elderly female and male subjects","volume":"43","author":"Lichtenstein","year":"2002","journal-title":"J Lipid Res"},{"key":"10.1016\/j.lpm.2013.01.053_bib0335","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/MOL.0b013e328340b8e7","article-title":"Lowering LDL cholesterol through diet: potential role in the statin era","volume":"22","author":"Bruckert","year":"2011","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.lpm.2013.01.053_bib0340","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/ajcn\/69.1.30","article-title":"Cholesterol lowering effects of dietary fiber: a meta-analysis","volume":"69","author":"Brown","year":"1999","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.lpm.2013.01.053_bib0345","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3945\/jn.108.095125","article-title":"Continuous dose-response relationship of the LDL cholesterol-lowering effect of phytosterol intake","volume":"139","author":"Demonty","year":"2009","journal-title":"J Nutr"},{"key":"10.1016\/j.lpm.2013.01.053_bib0350","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/ajcn\/56.2.320","article-title":"Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis","volume":"56","author":"Dattilo","year":"1992","journal-title":"Am J Clin Nutr"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.lpm.2013.01.053_bib0355","first-page":"I91","article-title":"Dietary treatment of familial hypercholesterolemia","volume":"9","author":"Connor","year":"1989","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.lpm.2013.01.053_bib0360","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.jada.2006.07.009","article-title":"Effects of a stanol-enriched diet on plasma cholesterol and triglycerides in patients treated with statins","volume":"106","author":"Castro Cabezas","year":"2006","journal-title":"J Am Diet Assoc"},{"key":"10.1016\/j.lpm.2013.01.053_bib0365","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.amjcard.2005.08.056","article-title":"Effect of plant stanol tablets on low-density lipoprotein cholesterol lowering in patients on statin drugs","volume":"97","author":"Goldberg","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.lpm.2013.01.053_bib0370","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2003.11.010","article-title":"Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia","volume":"173","author":"Civeira","year":"2004","journal-title":"Atherosclerosis"},{"issue":"Suppl. 3","key":"10.1016\/j.lpm.2013.01.053_bib0375","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.jacl.2011.04.001","article-title":"Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Ito","year":"2011","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.lpm.2013.01.053_bib0380","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0002-9149(97)00965-X","article-title":"Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES Study)","volume":"81","author":"Jones","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.lpm.2013.01.053_bib0385","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial)","volume":"92","author":"Jones","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.lpm.2013.01.053_bib0390","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.amjcard.2007.06.029","article-title":"Long-term efficacy and safety of rosuvastatin 40mg in patients with severe hypercholesterolemia","volume":"100","author":"Stein","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.lpm.2013.01.053_bib0395","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0140-6736(07)60716-8","article-title":"The safety of statins in clinical practice","volume":"370","author":"Armitage","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2013.01.053_bib0400","doi-asserted-by":"crossref","first-page":"C89","DOI":"10.1016\/j.amjcard.2006.02.030","article-title":"Final conclusions and recommendations oft he National Lipid Association Statin Safety Assessment Task Force","volume":"97","author":"Mc Kenney","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.lpm.2013.01.053_bib0405","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.cmet.2008.04.001","article-title":"The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1","volume":"7","author":"Ge","year":"2008","journal-title":"Cell Metab"},{"key":"10.1016\/j.lpm.2013.01.053_bib0410","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2796.2008.02062.x","article-title":"Ezetimibe monotherapy for cholesterol lowering in 2722\u00a0people: systematic review and meta-analysis of randomized controlled trials","volume":"265","author":"Pandor","year":"2009","journal-title":"J Intern Med"},{"key":"10.1016\/j.lpm.2013.01.053_bib0415","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2004.10.031","article-title":"Efficacy and safety of high-density lipoprotein cholesterol-increasing coumpounds. A meta-analysis of randomized controlled trials","volume":"45","author":"Birjmohun","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2013.01.053_bib0420","doi-asserted-by":"crossref","first-page":"e9220","DOI":"10.1371\/journal.pone.0009220","article-title":"Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal","volume":"5","author":"Huijgen","year":"2010","journal-title":"Plos One"},{"key":"10.1016\/j.lpm.2013.01.053_bib0425","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.atherosclerosis.2009.09.014","article-title":"Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands","volume":"209","author":"Pijlman","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.lpm.2013.01.053_bib0430","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ahj.2004.03.052","article-title":"Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin","volume":"148","author":"Stein","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.lpm.2013.01.053_bib0435","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2147\/VHRM.S13496","article-title":"Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia","volume":"6","author":"Hamilton-Craig","year":"2010","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.lpm.2013.01.053_bib0440","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.clinthera.2010.04.014","article-title":"Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomised, double-blind, controlled trial","volume":"32","author":"Huijgen","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.lpm.2013.01.053_bib0445","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.atherosclerosis.2008.02.009","article-title":"Recommendations for the use of LDL apheresis","volume":"198","author":"Thompson","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.lpm.2013.01.053_bib0450","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/MOL.0b013e3283402f53","article-title":"Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe","volume":"21","author":"Thompson","year":"2010","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.lpm.2013.01.053_bib0455","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.atherosclerosis.2009.06.010","article-title":"Efficacy criteria and cholesterol targets for LDL apheresis","volume":"208","author":"Thompson","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.lpm.2013.01.053_bib0460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(02)00251-4","article-title":"LDL apheresis","volume":"167","author":"Thompson","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.lpm.2013.01.053_bib0465","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/S0022-2275(20)37137-6","article-title":"Decreased production of low-density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia","volume":"38","author":"Marais","year":"1997","journal-title":"J Lipid Res"},{"key":"10.1016\/j.lpm.2013.01.053_bib0470","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/S0022-2275(20)39941-7","article-title":"Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-Co. A reductase inhibitor therapy","volume":"35","author":"Pfohl","year":"1994","journal-title":"J Lipid Res"},{"key":"10.1016\/j.lpm.2013.01.053_bib0475","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.atherosclerosis.2006.02.030","article-title":"A systematic review of LDL apheresis in the treatment of cardiovascular disease","volume":"189","author":"Thompsen","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.lpm.2013.01.053_bib0480","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0021-9150(92)90170-L","article-title":"Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesrolemia: a multicenter study. The LARS Investigators","volume":"95","author":"Tatami","year":"1992","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.lpm.2013.01.053_bib0485","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1007\/BF00190741","article-title":"The effect of LDL apheresis on progression of coronary artery disease in patients with familial hypercholesterolemia. Results of a multicenter LDL apheresis study","volume":"72","author":"Waidner","year":"1994","journal-title":"Clin Investig"},{"key":"10.1016\/j.lpm.2013.01.053_bib0490","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1365-2362.1994.tb01068.x","volume":"24","author":"Schuff-Werner","year":"1994","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.lpm.2013.01.053_bib0495","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0140-6736(95)92961-4","article-title":"Familial hypercholesterolemia regression study: a randomised trial of low-density-lipoprotein apheresis","volume":"345","author":"Thompson","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2013.01.053_bib0500","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1161\/01.CIR.93.10.1826","article-title":"LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment of coronary atherosclerosis","volume":"93","author":"Kroon","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2013.01.053_bib0505","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0002-9149(98)00692-4","article-title":"Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group","volume":"82","author":"Mabuchi","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.lpm.2013.01.053_bib0510","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S0026-0495(98)90127-5","article-title":"Long-term of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia","volume":"47","author":"Ritcher","year":"1998","journal-title":"Metabolism"},{"key":"10.1016\/j.lpm.2013.01.053_bib0515","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1161\/01.CIR.95.1.76","article-title":"Single LDL apheresis improves endothelium-dependent vasodilation in hypercholesterolemia humans","volume":"95","author":"Tamai","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2013.01.053_bib0520","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/jca.20000","article-title":"Improvement of endothelium-dependent coronary vasodilation after a single LDL apheresis in patients with hypercholesterolemia","volume":"19","author":"Igarashi","year":"2004","journal-title":"J Clin Apher"},{"key":"10.1016\/j.lpm.2013.01.053_bib0525","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1046\/j.1526-0968.2003.00078.x","article-title":"Changes in oxidative stress and microcirculation by low-density lipoprotein apheresis","volume":"7","author":"Sato","year":"2003","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.lpm.2013.01.053_bib0530","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1526-0968.2004.00172.x","article-title":"Evaluation of improtved coronary flow velocity reserve using transthoracic Doppler echocardiography after single LDL apheresis","volume":"8","author":"Kobayashi","year":"2004","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.lpm.2013.01.053_bib0535","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1515\/JPEM.2009.22.6.573","article-title":"Homozygous familial hypercholesterolemia","volume":"22","author":"Choh","year":"2009","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.lpm.2013.01.053_bib0540","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/ATVBAHA.108.163378","article-title":"Vascular calcification in homozygote familial hypercholesterolemia","volume":"28","author":"Morrisett","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.lpm.2013.01.053_bib0545","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/01.mol.0000137222.23784.2a","article-title":"Current management of severe homozygous hypercholesterolaemias","volume":"15","author":"Naoumova","year":"2004","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.lpm.2013.01.053_bib0550","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/meta.2002.34016","article-title":"Atorvastatin in low-density lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia","volume":"51","author":"Goldammer","year":"2002","journal-title":"Metabolism"},{"key":"10.1016\/j.lpm.2013.01.053_bib0555","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy","volume":"124","author":"Raal","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2013.01.053_bib0560","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","article-title":"Efficacy and safety of ezetimibe co-administered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia","volume":"105","author":"Gagn\u00e9","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2013.01.053_bib0565","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.amjcard.2008.06.049","article-title":"Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia","volume":"102","author":"Hudgins","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.lpm.2013.01.053_bib0570","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2013.01.053_bib0575","first-page":"103","article-title":"Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemia","volume":"13","author":"Rizzo","year":"2010","journal-title":"IDrugs"},{"key":"10.1016\/j.lpm.2013.01.053_bib0580","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1471-0528.2008.02084.x","article-title":"Management of fertility in women with familial hypercholesterolemia summary of a NICE guidance","volume":"116","author":"Thorogood","year":"2009","journal-title":"BJOG"},{"key":"10.1016\/j.lpm.2013.01.053_bib0585","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000293016","article-title":"Lipid profils during and after normal pregnancy","volume":"32","author":"Loke","year":"1991","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.lpm.2013.01.053_bib0590","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1042\/CS19980326","article-title":"Is normal pregnancy atherogenic?","volume":"96","author":"Martin","year":"1999","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.lpm.2013.01.053_bib0595","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.atherosclerosis.2006.01.002","article-title":"Marked changes in plasma lipids and lipoproteins during pregnancy in women with familial hypercholesterolemia","volume":"189","author":"Amundsen","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.lpm.2013.01.053_bib0600","first-page":"299","article-title":"Dilemmas in treatment of women with familial hypercholesterolemia during pregnancy","volume":"68","author":"Kusters","year":"2010","journal-title":"Neth J Med"},{"key":"10.1016\/j.lpm.2013.01.053_bib0605","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1046\/j.1526-0968.2003.00066.x","article-title":"Differential indication of lipoprotein apheresis during pregnancy","volume":"7","author":"Klingel","year":"2003","journal-title":"Ther Apher Dial"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498213004107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498213004107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,2,13]],"date-time":"2022-02-13T05:00:32Z","timestamp":1644728432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498213004107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":120,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0755498213004107"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2013.01.053","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}